Valuation: Tenax Therapeutics, Inc.

Market Cap 76.66M 69.91M 64.64M 58.34M 110M 7.16B 114M 781M 309M 3.87B 288M 282M 12.21B P/E 2026 *
-1.03x
P/E 2027 * -1.09x
Enterprise Value -8.54M -7.79M -7.2M -6.5M -12.24M -798M -12.72M -86.97M -34.38M -431M -32.04M -31.37M -1.36B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+0.70%
1 week-15.38%
Current month-20.11%
1 month+5.15%
3 months-15.88%
6 months-87.69%
Current year-88.27%
1 week 1.34
Extreme 1.34
1.64
1 month 1.34
Extreme 1.34
2.01
Current year 1.31
Extreme 1.31
19.4
1 year 1.31
Extreme 1.31
19.4
3 years 1.31
Extreme 1.31
33.44
5 years 1.31
Extreme 1.31
2,335.04
10 years 1.31
Extreme 1.31
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 70 25/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
21/10/26
Adar1 Capital Management LLC
BuyCompany 331,979 0.8871%
16/9/26 Buy

Director

53,000 0.1416%
15/9/26 Buy

Chief Executive Officer

4,850 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%-15.38%-81.39%-95.31% 76.12M
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -0.80%-5.14%+22.61%+142.41% 40B
Weighted average by Cap. -0.84%-3.65%+34.20%+143.93%

Financials

2026 *2027 *
Net sales - -
Net income -68.21M -62.2M -57.51M -51.9M -97.75M -6.37B -102M -695M -275M -3.44B -256M -251M -10.86B -74.14M -67.61M -62.52M -56.42M -106M -6.93B -110M -755M -298M -3.74B -278M -272M -11.81B
Net Debt -85.2M -77.7M -71.84M -64.84M -122M -7.96B -127M -868M -343M -4.3B -320M -313M -13.57B -10.2M -9.3M -8.6M -7.76M -14.62M -953M -15.19M -104M -41.06M -514M -38.27M -37.46M -1.62B
Projected Income Statement - Annual - Tenax Therapeutics, Inc.
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
18/11/26 USD 1.430 +0.70% 1,505,977
17/11/26 USD 1.420 -4.05% 1,154,390
16/11/26 USD 1.480 -8.64% 1,104,319
13/11/26 USD 1.620 +0.62% 901,931
12/11/26 USD 1.610 -4.73% 833,342
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tenax Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.430USD
Average target price
10.29USD
Spread / Average Target
+619.28%
  1. Stock Market
  2. Stocks
  3. TENX Stock